Mekasermin
Prijeđi na navigaciju
Prijeđi na pretragu
| Klinički podaci | |
|---|---|
| Robne marke | Increlex, Increlex (Tercica), Iplex |
| AHFS/Drugs.com | Monografija |
| Identifikatori | |
| CAS broj | 68562-41-4 |
| ATC kod | H01AC03 |
| DrugBank | DB01277 |
| ChEMBL[1] | CHEMBL1201716 
|
| Hemijski podaci | |
| Formula | C331H512N94O101S7 |
| Mol. masa | 7648.67 |
| Farmakokinetički podaci | |
| Poluvreme eliminacije | 2 h |
| Farmakoinformacioni podaci | |
| Trudnoća | ? |
| Pravni status | |
| Način primene | Subkutano |
Mekasermin INN, Increlex) je rekombinantni ljudski insulinu sličan faktor rasta 1 (IGF-I), koji se koristi kao dugoročni tretman neuspešnog rasta kod dece sa jakom deficijencijom primarnog IGF-I.[2][3] IGF-1 se sastoji od 70 aminokiselina u jednom lancu sa tri intramolekulska disulfidna mosta i molekulskom težinom od 7649 Daltona.[4][5][6][7][8][9][10]
Reference[uredi | uredi kod]
- ↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594.
- ↑ Fintini, D; Brufani, C; Cappa, M (2009). „Profile of mecasermin for the long-term treatment of growth failure in children and adolescents with severe primary IGF-1 deficiency”. Therapeutics and clinical risk management 5 (3): 553–9. PMC 2724186. PMID 19707272.
- ↑ „Increlex”. Drugs.com. Pristupljeno 10. 1. 2010.
- ↑ Keating GM: Mecasermin. BioDrugs. 2008;22(3):177-88. PMID 18481900
- ↑ Rosenbloom AL: Mecasermin (recombinant human insulin-like growth factor I). Adv Ther. 2009 Jan;26(1):40-54. Epub 2009 Jan 28. PMID 19198769
- ↑ Kemp SF: Insulin-like growth factor-I deficiency in children with growth hormone insensitivity: current and future treatment options. BioDrugs. 2009;23(3):155-63. doi: 10.2165/00063030-200923030-00002. PMID 19627167
- ↑ Rosenbloom AL: Is there a role for recombinant insulin-like growth factor-I in the treatment of idiopathic short stature? Lancet. 2006 Aug 12;368(9535):612-6. PMID 16905026
- ↑ Lewis ME, Neff NT, Contreras PC, Stong DB, Oppenheim RW, Grebow PE, Vaught JL: Insulin-like growth factor-I: potential for treatment of motor neuronal disorders. Exp Neurol. 1993 Nov;124(1):73-88. PMID 8282084
- ↑ Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035-41. DOI:10.1093/nar/gkq1126. PMC 3013709. PMID 21059682.
- ↑ David S. Wishart, Craig Knox, An Chi Guo, Dean Cheng, Savita Shrivastava, Dan Tzur, Bijaya Gautam, and Murtaza Hassanali (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Res 36 (Database issue): D901-6. DOI:10.1093/nar/gkm958. PMC 2238889. PMID 18048412.
Literatura[uredi | uredi kod]
- Hardman JG, Limbird LE, Gilman AG. (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10 izd.). New York: McGraw-Hill. DOI:10.1036/0071422803. ISBN 0-07-135469-7.
- Thomas L. Lemke, David A. Williams, ur. (2007). Foye's Principles of Medicinal Chemistry (6 izd.). Baltimore: Lippincott Willams & Wilkins. ISBN 0-7817-6879-9.
